Replication‐competent, oncolytic herpes simplex virus type 1 mutants induce a bystander effect following ganciclovir treatment

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Gene Medicine

• Publication date

  2007-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jgm.1085PMID 17685493
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intercellular trafficking and cytotoxicity of recombinant HSV-1 thymidine kinase fused with HSV-2 US11 RXP repeat peptide

  2007cited by this paper
• Herpes simplex virus blocks apoptosis by precluding mitochondrial cytochrome c release independent of caspase activation in infected human epithelial cells

  2006cited by this paper
• Herpes Simplex Virus ICP27 Is Required for Virus-Induced Stabilization of the ARE-Containing IEX-1 mRNA Encoded by the Human IER3 Gene

  2006cited by this paper
• Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma

  2006cited by this paper
• Tat8–TK/GCV Suicide Gene Therapy Induces Pancreatic Tumor Regression In Vivo

  2005cited by this paper
• Adenovirus Vector E4 Gene Regulates Connexin 40 and 43 Expression in Endothelial Cells via PKA and PI3K Signal Pathways

  2005cited by this paper
• Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer.

  2004cited by this paper
• Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice

  2003cited by this paper
• Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model.

  2003cited by this paper
• Influence of the bystander effect on HSV-tk/GCV gene therapy. A review.

  2002cited by this paper
• Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation

  2002cited by this paper
• Anti-apoptotic protein kinase of herpes simplex virus.

  2002cited by this paper
• Ser364 of connexin43 and the upregulation of gap junction assembly by cAMP

  2001cited by this paper
• VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death

  2001cited by this paper
• Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: Implications for gene therapeutic approaches

  2000cited by this paper
• Connexin 43-enhanced suicide gene therapy using herpesviral vectors.

  2000cited by this paper
• Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors

  2000cited by this paper
• Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3',5'-cyclic monophosphate, alpha-glycyrrhetinic acid, and cytosine arabinoside.

  2000influential reference
• HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma

  2000cited by this paper
• Rapid Phenotypic Characterization Method for Herpes Simplex Virus and Varicella-Zoster Virus Thymidine Kinases To Screen for Acyclovir-Resistant Viral Infection

  2000cited by this paper
• ICP22 and the UL13 Protein Kinase Are both Required for Herpes Simplex Virus-Induced Modification of the Large Subunit of RNA Polymerase II

  1999cited by this paper
• Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy.

  1999influential reference
• Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer

  1999cited by this paper
• Combination Gene Delivery of the Cell Cycle Inhibitor p27 with Thymidine Kinase Enhances Prodrug Cytotoxicity

  1998cited by this paper
• The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer.

  1997cited by this paper
• A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells.

  1997cited by this paper
• Suppression of apoptotic DNA fragmentation in herpes simplex virus type 1-infected cells

  1997cited by this paper
• Gene therapy for cancer: what have we done and where are we going?

  1997cited by this paper
• Role of connexin genes in growth control.

  1996cited by this paper
• Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins.

  1996cited by this paper
• cAMP promotes gap junctional coupling in T84 cells.

  1996cited by this paper
• Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival.

  1996cited by this paper
• Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action.

  1995cited by this paper
• The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro.

  1995cited by this paper
• The “Bystander Effect”: Association of U-87 Cell Death with Ganciclovir-Mediated Apoptosis of Nearby Cells and Lack of Effect in Athymic Mice

  1995cited by this paper
• Intercellular communication and carcinogenesis.

  1995cited by this paper
• Retinoids suppress proliferation, induce cell spreading, and up-regulate connexin43 expression only in postconfluent 10T1/2 cells: implications for the role of gap junctional communication.

  1994cited by this paper
• Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo.

  1994cited by this paper
• The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

  1993cited by this paper
• Carotenoids up-regulate connexin43 gene expression independent of their provitamin A or antioxidant properties.

  1992cited by this paper
• The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice.

  1991cited by this paper
• Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2

  1991cited by this paper
• Gap junction gene expression in human seizure disorder.

  1991cited by this paper
• Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant

  1988cited by this paper
• A single-base change within the DNA polymerase locus of herpes simplex virus type 2 can confer resistance to aphidicolin

  1987cited by this paper
• Degradation of cellular mRNA during infection by herpes simplex virus.

  1977cited by this paper

• Pseudorabies virus infection triggers pUL46-mediated phosphorylation of connexin-43 and closure of gap junctions to promote intercellular virus spread

  2025cites this paper
• Oncolytic viral therapy for gliomas: Advances in the mechanisms and approaches to delivery.

  2024cites this paper
• Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers

  2022cites this paper
• Oncolytic HSV Vectors and Anti-Tumor Immunity.

  2020cites this paper
• Oncolytic Herpes Simplex Viruses as a Paradigm for the Treatment of Cancer

  2018cites this paper
• Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials

  2017cites this paper
• Oncotarget Strategies For Herpes Simplex Virus-1.

  2016cites this paper
• Oncolytic virotherapy for urological cancers

  2016cites this paper
• Designing herpes viruses as oncolytics

  2015cites this paper
• An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment

  2014cites this paper
• Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling

  2011cites this paper
• ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

  2010cites this paper
• Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

  2010cites this paper
• Intelligent Design: Combination Therapy With Oncolytic Viruses.

  2010cites this paper
• Radiosensitization and Anti-tumour Effects of Cytosine Deaminase and Thymidine Kinase Fusion Suicide Gene in Human Adenoid Cystic Carcinoma Cells

  2009cites this paper